MITO
NASDAQStealth BioTherapeutics Corp. ADS
Latest news
25 items- SECSEC Form 15-12G filed by Stealth BioTherapeutics Corp. ADS15-12G - Stealth BioTherapeutics Corp (0001696396) (Filer)
- SECSEC Form EFFECT filed by Stealth BioTherapeutics Corp. ADSEFFECT - Stealth BioTherapeutics Corp (0001696396) (Filer)
- SECSEC Form EFFECT filed by Stealth BioTherapeutics Corp. ADSEFFECT - Stealth BioTherapeutics Corp (0001696396) (Filer)
- SECSEC Form EFFECT filed by Stealth BioTherapeutics Corp. ADSEFFECT - Stealth BioTherapeutics Corp (0001696396) (Filer)
- SECSEC Form S-8 POS filed by Stealth BioTherapeutics Corp. ADSS-8 POS - Stealth BioTherapeutics Corp (0001696396) (Filer)
- SECSEC Form S-8 POS filed by Stealth BioTherapeutics Corp. ADSS-8 POS - Stealth BioTherapeutics Corp (0001696396) (Filer)
- SECSEC Form S-8 POS filed by Stealth BioTherapeutics Corp. ADSS-8 POS - Stealth BioTherapeutics Corp (0001696396) (Filer)
- SECSEC Form S-8 POS filed by Stealth BioTherapeutics Corp. ADSS-8 POS - Stealth BioTherapeutics Corp (0001696396) (Filer)
- SECSEC Form POS AM filed by Stealth BioTherapeutics Corp. ADSPOS AM - Stealth BioTherapeutics Corp (0001696396) (Filer)
- SECSEC Form POS AM filed by Stealth BioTherapeutics Corp. ADSPOS AM - Stealth BioTherapeutics Corp (0001696396) (Filer)
- SECSEC Form POS AM filed by Stealth BioTherapeutics Corp. ADSPOS AM - Stealth BioTherapeutics Corp (0001696396) (Filer)
- SECSEC Form 6-K filed by Stealth BioTherapeutics Corp. ADS6-K - Stealth BioTherapeutics Corp (0001696396) (Filer)
- SECSEC Form SC 13E3/A filed by Stealth BioTherapeutics Corp. ADS (Amendment)SC 13E3/A - Stealth BioTherapeutics Corp (0001696396) (Subject)
- PRStealth BioTherapeutics Corp Announces Completion of MergerBOSTON, Nov. 16, 2022 /PRNewswire/ -- Stealth BioTherapeutics Corp (NASDAQ:MITO) (the "Company" or "Stealth BioTherapeutics"), a clinical-stage biotechnology company focused on the discovery, development, and commercialization of novel therapies for diseases involving mitochondrial dysfunction, announced today the completion of the merger (the "Merger") with Stealth Merger Sub Limited, an exempted company with limited liability incorporated under the law of the Cayman Islands ("Merger Sub"), pursuant to the previously announced Agreement and Plan of Merger, dated as of July 31, 2022 (the "Merger Agreement"), among the Company, Stealth Parent Limited, an exempted company with limited liabilit
- SECSEC Form 25-NSE filed by Stealth BioTherapeutics Corp. ADS25-NSE - Stealth BioTherapeutics Corp (0001696396) (Subject)
- NEWSStealth BioTherapeutics Announces SBT-272 Granted Orphan Drug Designation For Treatment Of ALSSBT-272 Phase 1 safety and tolerability data support further clinical development SBT-272 was neuroprotective and reduced neuroinflammation in ALS preclinical model SBT-272 Granted Orphan Drug Designation for Treatment of ALS BOSTON, Nov. 1, 2022 /PRNewswire/ -- Stealth BioTherapeutics Corp (NASDAQ:MITO), a clinical-stage biotechnology company focused on the discovery, development, and commercialization of novel therapies for diseases involving mitochondrial dysfunction, today announced encouraging Phase 1 data on the safety and tolerability of SBT-272, a next-generation small molecule designed to reach therapeutic concentrations in the brain and to restore mitochondrial structure and fun
- PRStealth BioTherapeutics Announces SBT-272 Data Updates and Orphan Drug Designation for the Treatment of Amyotrophic Lateral Sclerosis (ALS)SBT-272 Phase 1 safety and tolerability data support further clinical development SBT-272 was neuroprotective and reduced neuroinflammation in ALS preclinical model SBT-272 Granted Orphan Drug Designation for Treatment of ALS BOSTON, Nov. 1, 2022 /PRNewswire/ -- Stealth BioTherapeutics Corp (NASDAQ:MITO), a clinical-stage biotechnology company focused on the discovery, development, and commercialization of novel therapies for diseases involving mitochondrial dysfunction, today announced encouraging Phase 1 data on the safety and tolerability of SBT-272, a next-generation small molecule designed to reach therapeutic concentrations in the brain and to restore mitochondrial structure and functi
- SECSEC Form 6-K filed by Stealth BioTherapeutics Corp. ADS6-K - Stealth BioTherapeutics Corp (0001696396) (Filer)
- SECSEC Form SC 13E3/A filed by Stealth BioTherapeutics Corp. ADS (Amendment)SC 13E3/A - Stealth BioTherapeutics Corp (0001696396) (Subject)
- PRStealth BioTherapeutics Corp to Hold Extraordinary General Meeting of ShareholdersBOSTON, Oct. 7, 2022 /PRNewswire/ -- Stealth BioTherapeutics Corp (NASDAQ:MITO) ("Stealth" or the "Company"), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for diseases involving mitochondrial dysfunction, announced today that it has called an extraordinary general meeting of shareholders (the "EGM"), to be held at 9:30 a.m. (New York City time) on November 15, 2022, at Foley & Lardner LLP, 111 Huntington Ave Suite 2600, Boston, MA 02199, to consider and vote on, among other matters, the proposal to authorize and approve the previously announced agreement and plan of merger, dated as of July 31, 2022 (the "Merger Agreem
- SECSEC Form 6-K filed by Stealth BioTherapeutics Corp. ADS6-K - Stealth BioTherapeutics Corp (0001696396) (Filer)
- PRStealth BioTherapeutics Announces Departure of Chief Financial OfficerBOSTON, Sept. 30, 2022 /PRNewswire/ -- Stealth BioTherapeutics Corp (NASDAQ:MITO), a clinical-stage biotechnology company focused on the discovery, development, and commercialization of novel therapies for diseases involving mitochondrial dysfunction, today announced that Robert Weiskopf, Stealth's chief financial officer, is leaving the company effective September 30, 2022. Mr. Weiskopf joined Stealth in 2019 following the company's initial public offering to spearhead its public financial reporting activities and grow the Company's financial team. "On behalf of the entire te
- SECSEC Form SC 13E3/A filed by Stealth BioTherapeutics Corp. ADS (Amendment)SC 13E3/A - Stealth BioTherapeutics Corp (0001696396) (Subject)
- 13D/GSEC Form SC 13D/A filed by Stealth BioTherapeutics Corp. ADS (Amendment)SC 13D/A - Stealth BioTherapeutics Corp (0001696396) (Subject)
- PRStealth BioTherapeutics to Participate in Upcoming Ultra-Rare Disease EventsBOSTON, Sept. 15, 2022 /PRNewswire/ -- Stealth BioTherapeutics Corp (NASDAQ:MITO), a clinical-stage biotechnology company focused on the discovery, development, and commercialization of novel therapies for diseases involving mitochondrial dysfunction, today announced that the company is participating in upcoming events to discuss challenges and opportunities in ultra-rare disease drug development. Reenie McCarthy, Stealth's CEO, will be participating in "Rare Disease Research: A Prescription" hosted by STAT which will take place on Thursday, September 15th from 5:30 p.m.–9:00
MITO FAQ
7 questionsWhat does Stealth BioTherapeutics Corp. ADS do?
Stealth BioTherapeutics Corp, a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of therapies for diseases involving mitochondrial dysfunction. Its lead product candidate is Elamipretide that is in phase 3 clinical trial to treat barth syndrome, phase 2/3 clinical trial for the treatment of duchenne cardiomyopathy, phase 2a clinical trial to treat friedreich's ataxia, phase 2 clinical trial for the treatment of dry age-related macular degeneration, phase 2 clinical trial to treat leber's hereditary optic neuropathy, and phase 3 clinical trial...Where does MITO stock trade?
Stealth BioTherapeutics Corp. ADS (MITO) is listed on NASDAQ.What sector and industry is MITO in?
Stealth BioTherapeutics Corp. ADS operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Stealth BioTherapeutics Corp. ADS go public?
Stealth BioTherapeutics Corp. ADS (MITO) completed its IPO in 2019.What are analysts saying about MITO?
Stealth BioTherapeutics Corp. ADS has had 1 recent analyst action on file. The most recent action was from Maxim Group: Buy with a $300.00 price target on 2021-07-01. Recent price targets cluster around $300.00.What companies are similar to MITO?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), AZN (AstraZeneca PLC), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare MITO side-by-side with any of them on Quantisnow.How can I track MITO on Quantisnow?
Quantisnow aggregates Stealth BioTherapeutics Corp. ADS's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow MITO to receive live email and push alerts on every new disclosure.